Hikma Slashes Generics Forecast After Key Product Delay
Expected US Launch Of Authorized Generic Xyrem Slips To As Late As 2023
Just days after forecasting healthy generics sales growth for 2022, Hikma has significantly reduced its expectations for the year on news of a delay to its US launch of an authorized generic of Xyrem (sodium oxybate).
